Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg(Moffitt Cancer Center), Eric P. Krenning(Cyclotron (Netherlands)), Jack L. Erion(Moffitt Cancer Center), Matthew H. Kulke(Moffitt Cancer Center), Edward M. Wolin(University of Kentucky), Thomas M. O’Dorisio(University of Iowa), Martyn Caplin(The Royal Free Hospital), Thomas Thevenet(Moffitt Cancer Center), David Bushnell(Cytel (United States)), Andrew Hendifar(Cedars-Sinai Medical Center), Rachida Lebtahi(Hôpital Beaujon), Al B. Benson(Northwestern University), Paola Santoro(Moffitt Cancer Center), Enrique Grande(MD Anderson Cancer Center Madrid), Jordan Berlin(Dana-Farber Cancer Institute), Beth Chasen(The University of Texas MD Anderson Cancer Center), James C. Yao(The University of Texas MD Anderson Cancer Center), Richard P. Baum(Hessische Hochschule für Polizei und Verwaltung), Nicholas S. Reed(Beatson West of Scotland Cancer Centre), Rajaventhan Srirajaskanthan(Moffitt Cancer Center), Maribel Lopera Sierra(Moffitt Cancer Center), Heather A. Jacene(Brigham and Women's Hospital), Jaime Font de Mora(Bellvitge University Hospital), Ghassan El‐Haddad(Moffitt Cancer Center), Timothy J. Hobday(Mayo Clinic), Ettore Seregni(Fondazione IRCCS Istituto Nazionale dei Tumori), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Pamela L. Kunz(Moffitt Cancer Center), Kjell Öberg(Uppsala University Hospital), Marianne Pavel(Moffitt Cancer Center), Dik J. Kwekkeboom(Erasmus MC), Ebrahim S. Delpassand(Moffitt Cancer Center), Erik Mittra(Moffitt Cancer Center), Philippe Ruszniewski(Inserm), Harshad Kulkarni(Moffitt Cancer Center)
Cited by 3,163
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Bevacizumab in Combination With Oxaliplatin, Fluorouracil, and Leucovorin (FOLFOX4) for Previously Treated Metastatic Colorectal Cancer: Results From the Eastern Cooperative Oncology Group Study E3200
|Journal of Clinical Oncology|2007|2.3k
Maintenance Olaparib for Germline <i>BRCA</i> -Mutated Metastatic Pancreatic Cancer
|New England Journal of Medicine|2019|2.2k
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
|Journal of Clinical Oncology|2018|2.1k